Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock - Trial NCT05192213
Access comprehensive clinical trial information for NCT05192213 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hospital Sirio-Libanes and is currently Recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 1090 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hospital Sirio-Libanes
Timeline & Enrollment
Phase 3
Aug 01, 2021
Dec 20, 2023
Primary Outcome
28-day Mortality
Summary
A great interest exists regarding substances with an immunomodulatory effect for sepsis
 patients. Recent data have shown that intravenous vitamin C, together with corticosteroids
 and thiamine, could prevent progressive organ dysfunction and reduce vasopressor use in
 patients with severe sepsis and septic shock. Its effect on mortality, on the other hand, is
 yet to be demonstrated. The Vitamins study aims to conclusively determine, through its
 prospective, multicentre and double-blinded design including 1090 patients, wether Vitamin C,
 Thiamine and Hydrocortisone in combination can reduce mortality in patients with septic
 shock.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05192213
Non-Device Trial